PYXS Stock Analysis: Buy, Sell, or Hold?
PYXS - Pyxis Oncology, Inc. Common Stock
$1.45
-0.11 (-7.05%)
▼
WAIT
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 17, 2026
Get Alerted When PYXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PYXS is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PYXS is down 11.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PYXS is currently trading at $1.45, which is considered fair relative to its 30-day fair value range of $1.16 to $1.79.
Technical Outlook: Technically, PYXS is in a downtrend. The price is currently testing key support at $1.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.17 (+359.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PYXS is in a downtrend. The price is currently testing key support at $1.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.17 (+359.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$1.16 -
$1.79
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
Protect Your Profits
Holding PYXS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.1%)
- BULLISH: Trading 359.9% below Wall St target ($7.17)
- WARNING: Recommendation downgraded due to -11.0% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.16 -
$1.79
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$1.45
Resistance Level
$2.00
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-1.32
Wall Street Target
$7.18
(+359.9%)
Last updated: January 30, 2026 4:05 PM ET
Data refreshes hourly during market hours. Next update: 5:05 PM
Data refreshes hourly during market hours. Next update: 5:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PYXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$90 | 59 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$108 | 56 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$35 | 51 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$65 | 60 HOLD |
Advanced PYXS Option Strategies
Professional options setups generated by AI based on today's PYXS price and gamma walls.
